Taro Pharmaceutical Industries Ltd. Receives Tentative Approval For Augmented Betamethasone Dipropionate Lotion ANDA

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Jan. 26, 2006--Taro Pharmaceutical Industries Ltd. (Nasdaq: TARO) reported today that Taro Pharmaceuticals U.S.A., Inc., its U.S. affiliate, has received tentative approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application for Betamethasone Dipropionate Lotion (Augmented) USP, 0.05% ("augmented betamethasone dipropionate lotion"). The FDA has determined that Taro's augmented betamethasone dipropionate lotion is safe and effective for use when compared with the reference listed drug product, Schering Corporation's Diprolene(R) Lotion, 0.05% (Augmented).